


PHARMACEUTICAL 2021









PHARMACEUTICAL 2021



AVADEL PHARMACEUTICALS PLC Rank 58 of 409



The relative strengths and weaknesses of AVADEL PHARMACEUTICALS PLC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of AVADEL PHARMACEUTICALS PLC compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 120% points. The greatest weakness of AVADEL PHARMACEUTICALS PLC is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 111% points.

The company's Economic Capital Ratio, given in the ranking table, is 91%, being 446% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	263,454
Cost of Goods Sold	5,742
Intangible Assets	16,836
Liabilities, Current	15,109
Liabilities, Non-Current	134,262
Other Assets	30,988
Other Compr. Net Income	1,755
Other Expenses	-41,186
Other Liabilities	0
Other Net Income	2,097
Property and Equipment	359
Research and Development	20,442
Revenues	22,334
Selling, General and Administrative Expense	32,405

Output Variable	Value in 1000 USD
Assets	311,637
Liabilities	149,371
Expenses	17,403
Stockholders Equity	162,266
Net Income	7,028
Comprehensive Net Income	7,906
Economic Capital Ratio	91%